{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:16:21Z","timestamp":1792016181366,"version":"4.4.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by increased total kidney volume (TKV) and renal failure. This study aimed to determine if height-adjusted TKV (htTKV) predicts the onset of renal insufficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      This prospective, observational, longitudinal, multicenter study included 241 adults with ADPKD and preserved renal function. Magnetic resonance imaging and iothalamate clearance were used to measure htTKV and GFR, respectively. The association between baseline htTKV and the attainment of stage 3 CKD (GFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) during follow-up was determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After a mean follow-up of 7.9 years, stage 3 CKD was attained in 30.7% of the enrollees. Using baseline htTKV, negative correlations with GFR increased from \u22120.22 at baseline to \u22120.65 at year 8. In multivariable analysis, a baseline htTKV increase of 100 cc\/m significantly predicted the development of CKD within 8 years with an odds ratio of 1.48 (95% confidence interval: 1.29, 1.70). In receiver operator characteristic curve analysis, baseline htTKV of 600 cc\/m most accurately defined the risk of developing stage 3 CKD within 8 years with an area under the curve of 0.84 (95% confidence interval: 0.79, 0.90). htTKV was a better predictor than baseline age, serum creatinine, BUN, urinary albumin, or monocyte chemotactic protein-1 excretion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline htTKV \u2265600 cc\/m predicted the risk of developing renal insufficiency in ADPKD patients at high risk for renal disease progression within 8 years of follow-up, qualifying htTKV as a prognostic biomarker in ADPKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.09500911","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:07:07Z","timestamp":1329437227000},"page":"479-486","source":"Crossref","is-referenced-by-count":349,"title":["Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"7","author":[{"given":"Arlene B.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Guay-Woodford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyongtae Ty","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Landsittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard F.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis H.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marva","family":"Moxey-Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Flessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared J.","family":"Grantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20230811","first-page":"1","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families.","volume":"328","author":"Dalgaard","year":"1957","journal-title":"Acta Med Scand Suppl"},{"key":"R2-17-20230811","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease.","volume":"329","author":"Gabow","year":"1993","journal-title":"N Engl J Med"},{"key":"R3-17-20230811","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R4-17-20230811","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease.","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-17-20230811","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes.","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-17-20230811","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-17-20230811","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R8-17-20230811","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease.","volume":"8","author":"Johnson","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"R9-17-20230811","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ki.1990.330","article-title":"Renal structure and hypertension in autosomal dominant polycystic kidney disease.","volume":"38","author":"Gabow","year":"1990","journal-title":"Kidney Int"},{"key":"R10-17-20230811","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0272-6386(89)80068-X","article-title":"Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease.","volume":"14","author":"Gretz","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"R11-17-20230811","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","article-title":"Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study.","volume":"39","author":"Fick-Brosnahan","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R12-17-20230811","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.","volume":"17","author":"Harris","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R13-17-20230811","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"R14-17-20230811","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2215\/CJN.00030110","article-title":"Determinants and functional significance of renal parenchymal volume in adults.","volume":"6","author":"Johnson","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R15-17-20230811","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/01.ASN.0000013300.11876.37","article-title":"The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.","volume":"13","author":"Rossetti","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R16-17-20230811","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrneph.2009.214","article-title":"Imaging for the prognosis of autosomal dominant polycystic kidney disease.","volume":"6","author":"Bae","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R17-17-20230811","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months.","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"R18-17-20230811","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2215\/CJN.02251205","article-title":"Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: A progress report.","volume":"1","author":"Antiga","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-17-20230811","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"R20-17-20230811","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: Design and implementation.","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-17-20230811","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.V1181505","article-title":"Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease.","volume":"11","author":"King","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R22-17-20230811","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1046\/j.1523-1755.2000.00433.x","article-title":"Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography.","volume":"58","author":"Sise","year":"2000","journal-title":"Kidney Int"},{"key":"R23-17-20230811","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD.","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R25-17-20230811","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"R27-17-20230811","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"R28-17-20230811","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.","volume":"14","author":"Zheng","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R29-17-20230811","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1681\/ASN.V10112426","article-title":"Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group.","volume":"10","author":"Levey","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R30-17-20230811","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.ki.5002624","article-title":"Determinants of renal volume in autosomal dominant polycystic kidney disease.","volume":"73","author":"Grantham","year":"2008","journal-title":"Kidney Int"},{"key":"R31-17-20230811","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and family-based cohort followed for 22 years.","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R32-17-20230811","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1046\/j.1523-1755.2002.00326.x","article-title":"A complete mutation screen of the ADPKD genes by DHPLC.","volume":"61","author":"Rossetti","year":"2002","journal-title":"Kidney Int"},{"key":"R33-17-20230811","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2003.12.026","article-title":"Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.","volume":"43","author":"Wong","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R34-17-20230811","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1034\/j.1600-6143.2002.20310.x","article-title":"Can a transplanted living donor kidney function equivalently to its native partner?","volume":"2","author":"Velosa","year":"2002","journal-title":"Am J Transplant"},{"key":"R35-17-20230811","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease.","volume":"5","author":"Klahr","year":"1995","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201203000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:34Z","timestamp":1786369294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201203000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09500911","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}